Drug Profile
ABP 201
Alternative Names: ABP-201Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AbMed; AstraZeneca
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 24 Jan 2024 ABP 201 is still in preclinical development for Diabetic macular oedema and Wet age-related macular degeneration in USA (Intravitreous)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Injection)